This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
by Ahan Chakraborty
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
AMRNNegative Net Change ALLONegative Net Change INDVNegative Net Change
biotechs earnings medical
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
RDYPositive Net Change BMYPositive Net Change NVONegative Net Change AMRNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
by Zacks Equity Research
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
AMRNNegative Net Change AGIONegative Net Change LQDANegative Net Change INDVNegative Net Change
biotechs
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
by Sundeep Ganoria
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
JAZZNegative Net Change TLRYNegative Net Change VRNONegative Net Change
biotechs marijuana medical pot-stocks
New Strong Buy Stocks for May 13th
by Zacks Equity Research
HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.
NUENegative Net Change NKSHNegative Net Change HCSGNegative Net Change NEXANegative Net Change LQDANegative Net Change
biotechs finance industrial-products
GLP-1 Wars: Winners & Losers
by Andrew Rocco
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
JPMNegative Net Change KOPositive Net Change NVONegative Net Change LLYNegative Net Change PEPPositive Net Change MDLZNegative Net Change
biotechs
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
RHHBYNegative Net Change JNJNegative Net Change HALONegative Net Change ARGXNegative Net Change
biotechs earnings
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
by Zacks Equity Research
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
REGNNegative Net Change AMRNNegative Net Change NTLAPositive Net Change INDVNegative Net Change
biotechs
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
AMRNNegative Net Change CPRXPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals